Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease

This publication has 27 references indexed in Scilit:

• The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells
  Blood, 2013
• Anti-Thy-1 Antibody-mediated Complement-dependent Cytotoxicity is Regulated by the Distribution of Antigen, Antibody and Membrane Complement Regulatory Proteins in Rats
  Journal of Toxicologic Pathology, 2013
• Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice
  Arthritis Research & Therapy, 2012
• Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
  mAbs, 2010
• Experimental models of membranous nephropathy
  Drug Discovery Today: Disease Models, 2010
• PI3K limits TNF‐α production in CD16‐activated monocytes
  European Journal of Immunology, 2009
• The podocyte's response to injury: Role in proteinuria and glomerulosclerosis
  Kidney International, 2006
• Tetramolecular immune complexes are more efficient than IVIg to prevent antibody‐dependent in vitro and in vivo phagocytosis of blood cells
  British Journal of Haematology, 2004
• Opsonization of Apoptotic Cells by Autologous iC3b Facilitates Clearance by Immature Dendritic Cells, Down-regulates DR and CD86, and Up-regulates CC Chemokine Receptor 7
  Journal of Experimental Medicine, 2002
• Mesangiolysis: An update
  American Journal of Kidney Diseases, 1998